Condition

Malignant Pleural Effusion

ClinicalTrials.gov condition label

Clinical trials28
Recruiting5
Common interventions25
Lead sponsors shown15

Clinical trials

28 shown
Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseNCT07192900 · 2026-06-03
RECRUITING
Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary TumorsNCT07443020 · 2026-05-01
RECRUITING
A Study of MT027 in Patients with Pleural Malignant TumorsNCT06726564 · 2024-05-15
RECRUITING
Oncodrivers in Malignant Pleural Effusions Associated With Non-small Cell Lung Cancer: A Prospective Study.NCT04806412 · 2021-03-15
RECRUITING
UNC Pleural Fluid RegistryNCT05620329 · 2018-01-24
RECRUITING
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to DrugsNCT04985357 · 2024-11-01
WITHDRAWN
Cytological Examination of Malignant Pleural Effusion in Breast CancerNCT06657638 · 2024-10-19
COMPLETED
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including MesotheliomaNCT05278975 · 2022-03-31
COMPLETED
Value of Additional Upfront Systematic Lung Ultrasound in the Workup of Patients With Unilateral Pleural EffusionNCT04235998 · 2020-02-17
COMPLETED
Quantitative Diaphragmatic Ultrasound Evaluation in Pleural Effusions : A Feasability StudyNCT04264325 · 2020-01-31
COMPLETED
Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural EffusionNCT04131231 · 2019-10-15
UNKNOWN
A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural EffusionNCT03597009 · 2019-03-06
TERMINATED
A Randomized Study of Primary Tumor Radiotherapy for Patients With MPE Stage IV NSCLCNCT03987087 · 2018-09-01
UNKNOWN
Betadine Pleurodesis Via Tunneled Pleural CathetersNCT02975921 · 2018-07-01
WITHDRAWN
Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung CancerNCT02942043 · 2016-10-01
UNKNOWN
Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung CancerNCT02132884 · 2015-03-01
TERMINATED
Intrapleural Bevacizumab Injection for Malignant Effusion in Lung CancerNCT02054052 · 2014-01-01
COMPLETED
Intrapleural AdV-tk Therapy in Patients With Malignant Pleural EffusionNCT01997190 · 2013-10-01
COMPLETED
Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung CancerNCT01004510 · 2009-11-01
TERMINATED
Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung CancerNCT01661790 · 2009-08-01
COMPLETED
Tunneled Pleural Catheter in Partially Entrapped LungNCT00637676 · 2008-07-01
COMPLETED
AZD0530 in Treating Patients With Extensive Stage Small Cell Lung CancerNCT00528645 · 2007-11-01
COMPLETED
FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung CancerNCT00564733 · 2007-10-01
COMPLETED
Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerNCT00408460 · 2006-02-01
COMPLETED
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung CancerNCT00126581 · 2005-08-15
COMPLETED
Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerNCT00118183 · 2005-07-01
COMPLETED
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung CancerNCT00052338 · 2002-09-01
COMPLETED
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuNCT00004074 · 1999-08-01
COMPLETED

Common interventions

BevacizumabDRUG3CarboplatinDRUG3PaclitaxelDRUG3bortezomibDRUG2docetaxelDRUG2gemcitabine hydrochlorideDRUG2laboratory biomarker analysisOTHER2locally manufactured adoptive cellular therapy (ACT) productBIOLOGICAL2ABI-007/carboplatin/trastuzumabBIOLOGICAL1AdV-tk + valacyclovirBIOLOGICAL1cetuximabBIOLOGICAL1ChemotherapyDRUG1CisplatinDRUG1computed tomographyPROCEDURE1cytology specimen collection procedureOTHER1diaphragmatic ultrasound measureOTHER1ErlotinibDRUG1Erlotinib HydrochlorideDRUG1fludeoxyglucose F 18RADIATION1imaging biomarker analysisOTHER1imatinib mesylateDRUG1Interleukin-2DRUG1Interleukin-2 (IL-2)DRUG1meassurement of PD-L1, ALK, EGFRDIAGNOSTIC_TEST1microparticles packaging methotrexate (MPs-MTX)DRUG1

Leading sponsors

National Cancer Institute (NCI)5Naestved Hospital2UNC Lineberger Comprehensive Cancer Center2University of Washington2Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)1Candel Therapeutics, Inc.1Chinese PLA General Hospital1David Bartlett, MD1Fox Chase Cancer Center1Guizhou Medical University1Haihong Yang, MD, Pricipal investigator1Heidelberg University1Mansoura University Hospital1Peking Union Medical College1Peking University Cancer Hospital & Institute1

Trial status mix

COMPLETED15
RECRUITING5
TERMINATED3
UNKNOWN3
WITHDRAWN2

Phase mix

PHASE212
PHASE18
NA3
PHASE31
PHASE41

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.